Business Context and Reporting Period
Company: Pavmed Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 12, 2019
Event: Entry into a Material Definitive Agreement regarding a proposed equity offering.
Key Financial Metrics
- Offering Size: 1,680,000 shares of common stock.
- Price Per Share: $1.00.
- Gross Proceeds: $1,680,000.
- Estimated Net Proceeds: Approximately $1.6 million (after fees and expenses).
- Placement Agent Fee: 7% of gross proceeds from shares sold to purchasers introduced by the agent (Maxim Group LLC).
- Expense Reimbursement Cap: $30,000 for out-of-pocket accountable expenses.
- Existing Debt: Senior secured convertible note with an initial principal amount of $7,750,000 issued on December 27, 2018.
Material Changes and Transactions
The filing details a "reasonable best efforts" offering where 530,000 shares were sold to investors introduced by the placement agent, while the remaining shares were sold directly to purchasers. The transaction includes voting agreements requiring investors to support:
- An increase in authorized common stock from 75 million to 100 million shares.
- Issuance of shares under the existing senior secured convertible note to comply with Nasdaq stockholder approval rules.
The filing does not provide comparative financial data (revenue, profit, cash flow) for the current period versus the prior period, as this is a transactional report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
- Closing Date: Expected on or about April 16, 2019, subject to customary closing conditions.
- Regulatory Basis: The offering is made pursuant to an existing shelf registration statement on Form S-3 (Registration No. 333-220549).
- Emerging Growth Company: The registrant is designated as an emerging growth company.
- Indemnification: The Company agreed to indemnify the Placement Agent and Investors against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds once the transaction completes.
- Confirm the impact of the 100 million authorized share increase on existing shareholder dilution.
- Review the terms of the $7,750,000 senior secured convertible note to understand conversion mechanics and repayment obligations.
- Check subsequent filings for the final prospectus supplement and any changes to the offering terms.